Prot #CBYL719G12301: EPIK-B2: A Two Part, Phase III, Multicenter, Randomized (1:1), Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination with Trastuzumab and Pertuzumab as Maintenance Therapy in Pat

Project: Research project

Project Details

StatusActive
Effective start/end date7/1/2012/31/24

Funding

  • Novartis Pharmaceuticals Corporation (Prot #CBYL719G12301)